Chronic Obstructive Pulmonary Disease, An Issue of Clinics in Chest Medicine
- 1st Edition, Volume 41-3 - August 25, 2020
- Editors: Gerard Criner, Bartolome R. Celli
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 6 8 3 0 4 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 6 8 3 0 5 - 0
This issue of Clinics in Chest Medicine, guest-edited by Dr. Gerard Criner and Dr. Bartolome Celli, is focused on Chronic Obstructive Pulmonary Disease. Topics discussed in this… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis issue of Clinics in Chest Medicine, guest-edited by Dr. Gerard Criner and Dr. Bartolome Celli, is focused on Chronic Obstructive Pulmonary Disease. Topics discussed in this issue include but are not limited to: COPD Pathogenesis; Epidemiology of COPD; Host, Gender, and Early Life Factors as Risks for COPD; Alpha One Antitrypsin Deficiency; Lung Function Testing; Assessing Symptom Burden; Chest Imaging in the Diagnosis and Assessment of the Patient with COPD; Biomarkers in the Diagnosis and Assessment of COPD; Asthma/COPD Overlap; Multimorbidity in the Patient with COPD; Definition Causes, Pathogenesis, and Consequences of Exacerbations; Treatment of Acute Exacerbations; Prevention of Exacerbations; Bronchodilators; Benefits and Risks of Inhaled Corticosteroids in COPD; Systemic Medications; Smoking Cessation/Vaccinations; Pulmonary Rehabilitation; Oxygen Therapy/Noninvasive Ventilation; and Interventional and Surgical Therapies for COPD.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Clinics in Chest Medicine
- Preface
- Section I: COPD pathogenesis and risk factors
- Chronic Obstructive Pulmonary Disease Pathogenesis
- Key points
- Introduction
- The traditional understanding of chronic obstructive pulmonary disease: a self-inflicted disease caused by tobacco smoking (in males)
- Some observations do not fit this traditional pathogenic paradigm
- A new pathogenic understanding of chronic obstructive pulmonary disease: a balanced lung development and aging process determines lifelong lung function trajectories
- Implications
- Summary
- Epidemiology of Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Spirometric definition of chronic obstructive pulmonary disease
- Global epidemiology of chronic obstructive pulmonary disease
- Risk factors for chronic obstructive pulmonary disease
- Rural-urban disparities
- Racial/ethnic disparities
- Useful interventions to address chronic obstructive pulmonary disease disparities
- Summary
- Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Host factors
- Environmental and occupational exposures
- Early-life factors
- Summary
- Alpha-1 Antitrypsin Deficiency Associated COPD
- Key points
- Introduction
- Summary
- Section II: Diagnosis and Assessment of COPD
- Lung Function Testing in Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Structural and physiologic Basis of respiratory dysfunction in chronic obstructive pulmonary disease
- Lung function tests in the diagnostic assessment of chronic obstructive pulmonary disease
- Lung function tests in the assessment of disease severity
- Lung function tests in the indication for and responses to interventions
- Balanced recommendations
- Summary
- Assessing Symptom Burden
- Key points
- Introduction
- Assessment of symptoms
- Assessment of dyspnea
- Assessment of health status
- Chronic obstructive pulmonary disease assessment test
- Multidimensional scoring systems
- Thresholds for symptom assessment
- Conflict of interest statement
- Computerized Chest Imaging in the Diagnosis and Assessment of the Patient with Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Background
- Airways
- Beyond lung parenchyma and airways
- Clinical utilization of imaging in chronic obstructive pulmonary disease
- The path forward
- Summary
- Biomarkers in Chronic Obstructive Pulmonary Disease: The Gateway to Precision Medicine
- Key points
- Introduction
- The move toward precision medicine
- What is (and what is not) a biomarker?
- The current (and future) landscape of biomarkers in chronic obstructive lung disease
- Summary
- What Is Asthma Chronic Obstructive Pulmonary Disease Overlap?
- Key points
- Diseases and diagnoses
- Asthma and chronic obstructive pulmonary disease
- The importance of definitions
- Asthma chronic obstructive pulmonary disease overlap
- Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Dying from or with chronic obstructive pulmonary disease
- Epidemiology of chronic obstructive pulmonary disease–related comorbidities
- Comorbidities of clinical relevance in chronic obstructive pulmonary disease patients
- A novel approach to chronic obstructive pulmonary disease comorbidities
- Addressing the complexity of multimorbidity
- The use of novel tools to analyze complex interactions
- Summary
- Section III: Exacerbations
- Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations
- Key points
- Introduction
- Summary
- Treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Diagnosis
- Determination of etiology
- Determination of the severity of an exacerbation
- Site of treatment
- Outpatient management of chronic obstructive pulmonary disease exacerbation
- Hospital management of chronic obstructive pulmonary disease exacerbation
- Care on the general medical floor
- Care in the intensive care unit
- Summary
- Prevention of Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Primal and primary prevention
- Secondary prevention
- Tertiary prevention
- Summary
- Section IV: Pharmacologic Therapy in COPD
- Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?
- Key points
- Introduction
- Safety and clinical effectiveness of long-acting bronchodilators
- Long-acting beta-2 adrenoreceptor agonist versus placebo
- Long-acting muscarinic antagonist versus placebo
- Long-acting beta-2 agonist versus long-acting muscarinic antagonist
- Long-acting beta-2 agonist/long-acting muscarinic antagonist versus monocomponents
- Long-acting muscarinic antagonist versus long-acting beta-2 agonist/inhaled corticosteroid
- Long-acting beta-2 agonist/long-acting muscarinic antagonist versus long-acting beta-2 agonist/inhaled corticosteroid
- Impact of bronchodilators on dynamic hyperinflation and exercise performance
- Bronchodilators and comorbidities
- Factors to be considered when choosing molecules and devices
- Place of long-acting bronchodilators in guidelines and the clinical practice
- Summary
- Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks
- Key points
- Introduction
- Inhaled corticosteroid monotherapy
- Inhaled corticosteroid/long-acting beta-agonist therapy
- Trials of triple therapy with inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic antagonist
- Risks/safety
- Risk-benefit considerations
- Discussion
- Systemic Medications in Chronic Obstructive Pulmonary Disease: Use and Outcomes
- Key points
- Introduction
- Oral beta2-adrenergic agonists
- Xanthines, theophylline
- Phosphodiesterase 4 inhibitors
- Macrolides and other antibiotics
- Mucomodifiers
- Oral corticosteroids
- Antileukotrienes
- Cardiovascular/metabolic treatments
- Biologics
- Alpha1-antitrypsin augmentation therapy
- Systemic treatments for dyspnea
- Summary
- Section V: Non-pharmacological therapy in COPD
- Smoking Cessation/Vaccinations
- Key points
- Smoking cessation in chronic obstructive pulmonary disease
- Smoking prevalence in chronic obstructive pulmonary disease
- Characteristics of smokers with chronic obstructive pulmonary disease
- Smoking diagnosis in chronic obstructive pulmonary disease
- Smoking cessation treatments
- Smoking reduction
- E-cigarettes
- Vaccination in patients with chronic obstructive pulmonary disease
- Vaccination rates
- Influenza disease
- Pneumococcal diseases in patients with chronic obstructive pulmonary disease
- Summary
- Pulmonary Rehabilitation
- Key points
- Introduction
- Definition, concept and source documentations
- Exercise training, testing and prescription in pulmonary rehabilitation
- Pulmonary rehabilitation patient selection, setting, and delivery
- Behavior modification, exercise maintenance, and increased physical activity
- Pulmonary rehabilitation, acute exacerbations, and advanced disease
- Summary
- Oxygen Therapy and Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Supplemental oxygen therapy in chronic obstructive pulmonary disease
- Noninvasive ventilation in chronic obstructive pulmonary disease
- Summary
- Interventional Bronchoscopic Therapies for Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Bronchoscopic approaches to lung volume reduction
- Targeted lung denervation
- Summary
- Surgical Therapies for Chronic Obstructive Pulmonary Disease
- Key points
- Introduction
- Rationale for lung volume reduction
- History of lung volume reduction surgery
- The National Emphysema Treatment Trial
- Lung volume reduction surgery: current state
- Bullectomy
- Lung transplantation in chronic obstructive pulmonary disease
- Summary
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 41-3
- Published: August 25, 2020
- Imprint: Elsevier
- Hardback ISBN: 9780323683043
- eBook ISBN: 9780323683050
BC
Bartolome R. Celli
Affiliations and expertise
Chief, Pulmonary and Critical Care Medicine, St. Elizabeth's Medical Center Professor of Medicine, Tufts University, Boston, MA